News in Drug Development & AI
summary
Tissue Dynamics combines organ-on-chip 3D human microtissues with internal sensors and robotics to run 20,000 microtissues in parallel, claim automated lead optimization, and report a past detection of troglitazone’s human liver toxicity missed by animal tests. A recent animal-free kidney program runs from mechanism to combination therapy in ~12 months and lands on the cover of Science Translational Medicine. The company projects cutting clinical failure risk by ~85% and lowering cost per drug from $2.6B to ~$0.5B.
AI-written summary · about
chapters (9)
- 0:00Drug development challenges
- 2:39Current process flaws
- 5:09Organ-on-a-chip tech
- 7:38Bionic micro organs & AI
- 9:00Autonomous drug dev with AI
- 11:08Clinical trials & real-world use
- 13:12Economic & healthcare impact
- 15:20Democratizing healthcare
- 16:45Closing remarks
related talks
30mAI in Drug Discovery
30mMachine Learning: A New Approach to Drug Discovery
20mTranslating a Trillion Pointo Diseases of Data into Therapies
44mNext-Gen Therapies
10mGenesis Final Round: Nanyang Biologics
34mThe True Revolution Lies Ahead of Us
08mEngineering the Future of Pharma: AI-Driven Drug Discovery
23mAI in the Life Science Sector